|
|
Sold Out
Book Categories |
| Preface | ||
| Chapter 1 | Clinical Pharmacology of SERMs and Pure Anti-estrogens | 1 |
| Chapter 2 | Aromatase Inhibitors: The Third Generation | 17 |
| Chapter 3 | Systemic Therapy of Metastatic Breast Cancer in Postmenopausal Patients | 13 |
| Chapter 4 | ATAC: Early Breast Cancer | 47 |
| Chapter 5 | Aromatase Inhibitors and Other Agents in Early-Stage Breast Cancer | 55 |
| Chapter 6 | Neoadjuvant Therapy in Postmenopausal Women | 73 |
| Panel Discussion 1 | Therapy in Postmenopausal Women | 87 |
| Chapter 7 | Endocrine Therapy for Advanced Breast Cancer in Premenopausal Women | 105 |
| Chapter 8 | Adjuvant Endocrine Treatment in Premenopausal Patients | 115 |
| Chapter 9 | Adjuvant Chemotherapy in Breast Cancer Patients with Hormone-Receptor-Positive (Responsive) Disease: Focus on Premenopausal Women | 127 |
| Panel Discussion 2 | Therapy in Premenopausal Women | 137 |
| Chapter 10 | Biology of Premalignant Lesions and Pathogenesis | 153 |
| Chapter 11 | Estradiol-Induced Carcinogenesis via Formation of Genotoxic Metabolites | |
| Chapter 12 | Beyond Tamoxifen: Results of Clinical Trials | 179 |
| Chapter 13 | Clinical Trials with Aromatase Inhibitors for the Prevention of Breast Cancer | 189 |
| Panel Discussion 3 | Chemoprevention | 203 |
| Chapter 14 | Crosstalk Between Estrogen-Receptor and Growth-Factor-Receptor Pathways as a Mechanism of Endocrine Therapy Resistance | 215 |
| Chapter 15 | ErbB2/HER-2 and Other Molecular Pathways in Estrogen-Receptor-Positive Breast Cancer: Impact on Endocrine Resistance and Clinical Outcome | 229 |
| Chapter 16 | Beyond Antihormones in the Targeted Therapy of Breast Cancer | |
| Chapter 17 | Novel Therapeutics | 259 |
| Chapter 18 | Surrogate Biomarkers and Neoadjuvant Endocrine Therapy | 269 |
| Chapter 19 | Aromatase Localization in Human Breast Cancer with Development of New Antibodies | |
| Panel Discussion 4 | Biology and New Therapeutics | 287 |
| Panel Discussion 5 | Final Discussion and Wrap-up | 295 |
| Index | 311 |
| Price | Condition | Delivery | Seller | Action |
| $99.99 | Digital |
| WonderClub |
David Lomax
reviewed Endocrine Therapy for Breast Cancer on October 01, 2014
Endocrine Therapy for Breast Cancer
I found this book out of sheer desperation...my body has really been kicking my butt since I turned 40. It was definitely a relief to know that other women go through this Change before the Change. I'm not thrilled that I may continue to go through it for a WHOLE DECADE.....AAAAARGH!! but the book was reassuring.
Warning, for those like me who are reluctant to take the Pill or hormones, the author definitely comes down on the side of modern medical science. I think he was kind of dismissive of natural healing methods and pretty much raving about how great the low-dose Pill is. In fact, in my case, I cannot take the Pill because it sends my blood pressure through the roof. (Whether or not this has been properly researched, it is a fact in my case. I went off the pill and the BP was back to normal in a couple weeks. Iron replacement therapy, on the other hand, is well-documented and has done wonders for me).
That said, I agree with his statement that, if we really wanted to be 100 per cent natural, women would have 8 or more children and would be lucky to make it to age 50 at all! And, I also agree with him that we should all be careful, informed consumers and not be hesitant to ask questions and do research.
Login|Complaints|Blog|Games|Digital Media|Souls|Obituary|Contact Us|FAQ
CAN'T FIND WHAT YOU'RE LOOKING FOR? CLICK HERE!!! X
You must be logged in to add to WishlistX
This item is in your Wish List
X
This item is in your Collection
Endocrine Therapy for Breast Cancer
X
This Item is in Your Inventory
Endocrine Therapy for Breast Cancer
X
You must be logged in to review the productsX
X
X
Add Endocrine Therapy for Breast Cancer, Because of the predominant role estrogens play in the development of breast cancer and the limited effectiveness of tamoxifen therapy, more selective therapeutics targeting estrogen signaling have been developed: selective estrogen receptor modulators (SE, Endocrine Therapy for Breast Cancer to the inventory that you are selling on WonderClubX
X
Add Endocrine Therapy for Breast Cancer, Because of the predominant role estrogens play in the development of breast cancer and the limited effectiveness of tamoxifen therapy, more selective therapeutics targeting estrogen signaling have been developed: selective estrogen receptor modulators (SE, Endocrine Therapy for Breast Cancer to your collection on WonderClub |